Datopotamab Deruxtecan, often abbreviated as DATO, represents an notable advancement within targeted cancer therapy. This new antibody-drug conjugate joins an monoclonal antibody specifically focused on HER-2 expressing cells with a potent cytotoxic payload, deruxtecan. The process of action includes the antibody's power to bind to tumor cells, sub